Does PRALSETINIB Cause Interstitial lung disease? 26 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 26 reports of Interstitial lung disease have been filed in association with PRALSETINIB (Gavreto). This represents 1.8% of all adverse event reports for PRALSETINIB.
26
Reports of Interstitial lung disease with PRALSETINIB
1.8%
of all PRALSETINIB reports
3
Deaths
20
Hospitalizations
How Dangerous Is Interstitial lung disease From PRALSETINIB?
Of the 26 reports, 3 (11.5%) resulted in death, 20 (76.9%) required hospitalization.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for PRALSETINIB.
What Other Side Effects Does PRALSETINIB Cause?
Death (126)
Fatigue (104)
Asthenia (96)
Off label use (92)
Hypertension (89)
Disease progression (85)
Anaemia (80)
Diarrhoea (79)
Pyrexia (75)
White blood cell count decreased (74)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which PRALSETINIB Alternatives Have Lower Interstitial lung disease Risk?
PRALSETINIB vs PRAMIPEXOLE
PRALSETINIB vs PRAMIPEXOLE\PRAMIPEXOLE
PRALSETINIB vs PRAMLINTIDE
PRALSETINIB vs PRASTERONE
PRALSETINIB vs PRASUGREL